Allergy Therapeutics gets approval for vaccine technology patent

By Elaine Rigoli

Tampa, Fla., May 11 - Allergy Therapeutics plc has been granted a broad technology patent for the combination of MPL with tyrosine and an antigen by the European Patent Office, covering 24 countries in Europe.

The patent covers vaccine therapy for any bacterial or viral disease and uses an antigen derived from the target organism, the company said in a news release.

Therefore, the advanced MPL and tyrosine adjuvant combination, which the company already uses in its therapeutic allergy vaccines, may be employed as an anti-infective, administered as a preventive vaccine, the release said.

The company said MPL is classified as a TLR4 agonist that acts as a Th1-inducing adjuvant; the adjuvant qualities are enhanced in the presence of tyrosine.

This combination induces a shift in the immune response (incorporating the production of cytotoxic T cells), effective for when the disease organism is intracellular, for example with viruses and some bacterial species.

The patent also covers the use of this advanced adjuvant system in cancer immunotherapy in addition to bacterial and viral immunotherapy.

Allergy Therapeutics, located in West Sussex, United Kingdom, is a pharmaceutical company focused on allergy vaccination.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.